基于PIVKA-II的模型用于DAA治愈HCV相关肝硬化患者的HCC风险分层:开发与验证
研究纳入1220例经DAA治疗获得SVR的HCV相关肝硬化患者,回顾性分为训练队列(都灵+比萨,93例发生HCC)和验证队列(米兰,19例发生HCC)。基于PIVKA-II联合年龄、性别、ALT、AST、γGT、血小板、白蛋白和总胆红素的Cox模型在训练队列C-index为0.72,验证队列C-index为0.71,识别随访前12个月发生HCC的AUC为0.84。低、中、高风险组HCC累积发生率分别为2.7%、4.0%和14.3%(p<0.001),低风险组随访3年内无HCC发生。
要点
- 基于PIVKA-II的模型在训练队列C-index为0.72、验证队列C-index为0.71。
- 验证队列中模型识别随访前12个月发生HCC的AUC为0.84。
- 低、中、高风险组HCC累积发生率分别为2.7%、4.0%和14.3%(p<0.001),低风险组随访3年内无HCC发生。
核心结论
- 基于PIVKA-II的模型对DAA治愈的HCV相关肝硬化患者HCC风险分层显示出令人满意的准确性,可能有助于实施基于风险的监测方案。
研究设计与样本
- 研究纳入1220例经DAA治疗的HCV相关肝硬化连续患者(都灵531例、比萨335例、米兰354例)。
- 患者被回顾性分配至训练队列(都灵+比萨;中位随访39个月,范围22-55个月;发生HCC 93例[10.7%])和验证队列(米兰;中位随访49.0个月,范围35.0-52.0个月;发生HCC 19例[5.4%])。
- 血清PIVKA-II采用LumipulseG系统(Fujirebio,日本)在SVR12(都灵和比萨队列)或治疗结束时(米兰队列)检测。
主要发现
- 采用Cox回归分析,从训练队列导出包含PIVKA-II联合年龄、性别、ALT、AST、γGT、血小板计数、白蛋白和总胆红素的模型(C-index=0.72)。
- 验证队列中模型C-index为0.71,识别随访前12个月发生HCC的AUC为0.84。
- 按三个风险类别分组,低、中、高风险组HCC累积发生率分别为2.7%、4.0%和14.3%(p<0.001)。
- 低风险组随访3年内无HCC发生。
关键数值与推荐
- 训练队列模型C-index=0.72,验证队列C-index=0.71。
- 验证队列识别随访前12个月发生HCC的AUC=0.84。
- 低、中、高风险组HCC累积发生率分别为2.7%、4.0%和14.3%(p<0.001)。
临床怎么用
- 作者认为该基于PIVKA-II的模型可能作为实施基于风险的监测方案的有价值工具。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAA) remain at risk of developing hepatocellular carcinoma (HCC). Recently, serum protein induced by vitamin K absence or antagonist-II (PIVKA-II) has shown promising results as an HCC-predictive biomarker. We aimed to develop and validate a PIVKA-II-based model for HCC risk stratification in cirrhotic patients with SVR to DAA. METHODS: A total of 1220 consecutive patients (Turin, n = 531; Pisa, n = 335; Milan, n = 354) with HCV-related cirrhosis treated with DAA were included in the study. Patients were retrospectively allocated to the training cohort (Turin+Pisa; median follow-up [FU] 39, 22-55 months; incident HCC: 93 [10.7%]) and validation cohort (Milan; median FU 49.0, 35.0-52.0 months; incident HCC: 19 [5.4%]). Serum PIVKA-II levels were measured using the LumipulseG system (Fujirebio, Japan) at SVR12 (Turin and Pisa cohorts) or the end of treatment (Milan cohort). RESULTS: Using Cox regression analysis, a model including PIVKA-II combined with age, sex, ALT, AST, γGT, platelet count, albumin and total bilirubin was derived from the training cohort (C-index = 0.72). In the validation cohort, the model showed a C-index of 0.71 with an area under the curve of 0.84 for identifying patients who developed HCC during the first 12 months of FU. When patients were grouped into three risk categories, the cumulative incidence of HCC was 2.7%, 4.0% and 14.3% in the low-, medium- and high-risk groups, respectively (p < 0.001). Notably, no HCC occurred within 3 years of FU in the low-risk group. CONCLUSIONS: Our PIVKA-II-based model showed satisfactory accuracy for HCC risk stratification and may represent a valuable tool for implementing risk-based surveillance protocols in patients with HCV-related cirrhosis with SVR to DAA.
引用
- Caviglia GP, Fariselli P, D'Ambrosio R, et al. Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA. Aliment Pharmacol Ther. 2024. PMID: 39569574. doi:10.1111/apt.18409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。